Lee's Pharmaceutical, ScinoPharm Taiwan deal

Lee's and ScinoPharm partnered to develop, produce and commercialize fondaparinux, travoprost and bimatoprost in China. Fondaparinux is an antithrombotic that selectively inhibits Factor Xa, and travoprost and bimatoprost are prostaglandin analogs. Lee's will have exclusive rights to commercialize the products in China.

Under the deal, ScinoPharm will provide API for fondaparinux and grant Lee's an exclusive license to ScinoPharm's formulation technology in China. Lee's will be responsible for manufacturing the formulated product in China. Lee's will submit a regulatory application to China's Food and Drug Administration (CFDA) next year, with a launch expected in 2018...